Please login to the form below

Not currently logged in
Email:
Password:

Cystic fibrosis drug disappoints in trial

Shares of Inspire Pharma have fallen by 58 per cent after its cystic fibrosis drug denufosol tetrasodium failed to meet expectations in a phase III trial

Shares of Inspire Pharma have fallen by 58 per cent after its cystic fibrosis drug denufosol tetrasodium failed to meet expectations in a phase III trial.

The drop in value to $3.49 per share is a two-year low for the US-based company, and follows the announcement of top-line results from the TIGER-2 clinical trial.

The trial involved 466 patients and investigated the efficacy and safety of denufosol compared to placebo. It was found that there was no statistical significance for the trial's primary efficacy endpoint of improved lung function after 48 weeks.

No significant difference between denufosol and placebo were reported for three key secondary endpoints either.

"These TIGER-2 results were disappointing and unexpected given the treatment effect observed in the TIGER-1 trial,” said Adrian Adams, president and CEO of Inspire. "We will conduct a thorough analysis of the data to fully understand the results from this trial and the impact on any future development of denufosol and on the company going forward. We expect to provide a detailed corporate update by mid-February. Meanwhile, we will continue to focus on our ophthalmology business."

Inspire has further advised patients taking denufosol as part of the separate DEFY trial to discontinue treatment with the product due to a 'lack of meaningful benefit'.

The company will issue further guidance regarding the DEFY trial in the near future.

4th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...